T · 3386.T
Cosmo Bio Company,Limited
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Tokyo 135-0016
- Website
- cosmobio.co.jp
Price · as of 2025-12-31
$1,262.00
Market cap 7.78B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,663.67 | +31.83% |
| Intrinsic Value(DCF) | $542.80 | -56.99% |
| Graham-Dodd Method(GD) | $1,025.63 | -18.73% |
| Graham Formula(GF) | $887.23 | -29.7% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $775.11 | ||||
| 2020 | $990.06 | $1,290.33 | $262.97 | $1,571.72 | $1,642.22 |
| 2021 | $837.82 | $1,499.91 | $3,295.37 | $1,398.74 | $2,730.61 |
| 2022 | $876.60 | $1,449.97 | $16.44 | $1,232.83 | $1,013.69 |
| 2023 | $900.07 | $1,226.55 | $0.00 | $1,321.10 | $456.99 |
| 2024 | $1,065.81 | $1,363.23 | $0.00 | $1,315.71 | $685.14 |
| 2025 | $1,357.00 | $1,663.67 | $0.00 | $1,025.63 | $887.23 |
AI valuation
Our deep-learning model estimates Cosmo Bio Company,Limited's (3386.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,663.67
- Current price
- $1,262.00
- AI upside
- +31.83%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$542.80
-56.99% upside
Graham-Dodd
$1,025.63
-18.73% upside
Graham Formula
$887.23
-29.7% upside
About Cosmo Bio Company,Limited
Cosmo Bio Company,Limited engages in the import, export, manufacture, marketing, and sale of life science research biotools. Its life science research tools include reagents, kits, instruments, software, and diagnostics products. The company offers research reagents, such as antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, bacteria, and others, as well as offers detection reagents, cell and tissue culture systems, gene analysis systems, and others. It also provides research instruments comprising electrophoresis apparatuses, cell culture labware, gene manipulation systems, data analysis software, and others; drug discovery and custom research services; and clinical diagnostics. In addition, the company develops and manufactures cell/cell culture products, including adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, mesenchymal stem, and feeder cells, as well as tumor cell lines, coating reagents, macrophage-related products, etc.; and assay kit related products that comprise various measurement kits, staining kits, detection/purification kits, etc. Further, it offers biotechnology research equipment, which include constant-temperature transport containers, aluminum block mat heat insulation devices, dew condensation prevention glass plates, etc.; and consigned, custom peptide synthesis, and antibody production services. The company serves laboratories, research institutes, and life-science education and testing organizations. It sells its products through outlets in Japan, as well as a network of sales agents internationally. Cosmo Bio Company,Limited was founded in 1978 and is headquartered in Tokyo, Japan.
- CEO
- Norihiko Shibayama
- Employees
- 174
- Beta
- 0.06
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($542.80 ÷ $1,262.00) − 1 = -56.99% (DCF, example).